Lineage Cell Therapeutics Inc (AMEX:LCTX) shares, rose in value on Thursday, March 27, with the stock price down by -0.70% to the previous day’s close as strong demand from buyers drove the stock to $0.50.
Actively observing the price movement in the last trading, the stock closed the session at $0.50, falling within a range of $0.4725 and $0.5078. The value of beta (5-year monthly) was 1.278. Referring to stock’s 52-week performance, its high was $1.61, and the low was $0.48. On the whole, LCTX has fluctuated by -20.73% over the past month.
With the market capitalization of Lineage Cell Therapeutics Inc currently standing at about $113.40 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-09.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.72M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LCTX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of LCTX currently trading nearly -3.89% and -16.54% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 38.69, while the 7-day volatility ratio is showing 7.57% which for the 30-day chart, stands at 8.84%. Furthermore, Lineage Cell Therapeutics Inc (LCTX)’s beta value is 1.29, and its average true range (ATR) is 0.04.
A comparison of Lineage Cell Therapeutics Inc (LCTX) with its peers suggests the former has fared considerably weaker in the market. LCTX showed an intraday change of -0.70% in last session, and over the past year, it shrunk by -61.20%%.
Data on historical trading for Lineage Cell Therapeutics Inc (AMEX:LCTX) indicates that the trading volumes over the past 10 days have averaged 2.1 and over the past 3 months, they’ve averaged 1.83 million. According to company’s latest data on outstanding shares, there are 228.36 million shares outstanding.
Nearly 0.44% of Lineage Cell Therapeutics Inc’s shares belong to company insiders and institutional investors own 51.10% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 22.34 million shares as on 2025-03-14, resulting in a short ratio of 18.33. According to the data, the short interest in Lineage Cell Therapeutics Inc (LCTX) stood at 1551.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 21.55 million. The stock has fallen by -1.17% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LCTX stock heading into the next quarter.
